10-Q: Vaccinex Reports Q3 2024 Results, Faces Nasdaq Delisting Risk Despite Positive Clinical Data

Sentiment:

Quarterly Report 14 November 2024 4:45 PM

Vaccinex reported its Q3 2024 financial results, highlighting a net loss and ongoing concerns about its ability to continue as a going concern, while also announcing positive clinical trial data for its Alzheimer's drug candidate.

Capital raiseThe company raised approximately $14.1 million through private placements, a public offering, and the exercise of warrants during the nine months ended September 30, 2024.The company is exploring various financing strategies, including public or private equity sales, debt financing, and strategic alliances, to address its liquidity concerns.On November 13, 2024, the Company entered into a securities purchase agreement pursuant to which the Company issued and sold to the purchasers named therein an aggregate of 76,909 shares of the Companys common stock and pre-funded warrants to purchase up to 584,646 shares of Common Stock for aggregate gross proceeds to the Company of approximately $2.15 million.

Worse than expectedThe company's financial results were worse than expected due to a net loss of $5.7 million for Q3 2024 and a going concern warning due to insufficient liquidity.The company is at risk of being delisted from the Nasdaq Capital Market due to not meeting the minimum stockholders' equity requirement.

Summary

Vaccinex, a clinical-stage biotechnology company, announced its financial results for the third quarter of 2024, revealing a net loss of $5.7 million, compared to a $4.9 million loss in the same period last year.
The company's revenue for the quarter was $52,000, a slight increase from $20,000 in Q3 2023, while research and development expenses decreased to $3.2 million from $4.4 million year-over-year.
For the nine months ended September 30, 2024, Vaccinex reported a net loss of $15.3 million, compared to $16.9 million for the same period in 2023, with revenue of $388,000 and $570,000 respectively.
The company's cash and cash equivalents stood at $2.9 million as of September 30, 2024, up from $1.5 million at the end of 2023.
Vaccinex is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum stockholders' equity requirement, despite appealing the decision.
The company's lead drug candidate, pepinemab, showed a statistically significant increase in brain metabolic activity in patients with mild cognitive impairment due to Alzheimer's disease in the SIGNAL-AD trial.
The company has raised approximately $14.1 million through private placements, a public offering, and the exercise of warrants during the nine months ended September 30, 2024.
Vaccinex is exploring various financing strategies, including public or private equity sales, debt financing, and strategic alliances, to address its liquidity concerns.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial results for pepinemab, the company's financial situation is precarious, with a going concern warning and the risk of Nasdaq delisting. The positive clinical data is offset by the negative financial outlook and the potential for significant dilution from future capital raises.

Positives

Pepinemab demonstrated a statistically significant increase in brain metabolic activity in the medial temporal cortex of patients with mild cognitive impairment due to Alzheimer's disease.
The company successfully raised $14.1 million through various financing activities, improving its cash position.
The company's research and development expenses decreased by 27% in Q3 2024 compared to Q3 2023.
The company's collaboration with Merck for head and neck cancer and with Merck KGaA for pancreatic cancer are ongoing.
The company has a collaboration with the Alzheimers Drug Discovery Foundation.

Negatives

The company reported a net loss of $5.7 million for Q3 2024 and $15.3 million for the nine months ended September 30, 2024.
Vaccinex is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum stockholders' equity requirement.
The company has a going concern warning due to insufficient liquidity to sustain operations for the next year.
A holder of certain warrants believes their warrants are still outstanding, which could lead to adverse impacts for the company.
The company has not generated any revenue from sales of its product candidates to date.

Risks

The company's ability to continue as a going concern is uncertain due to significant losses and negative cash flows.
There is a risk of delisting from the Nasdaq Capital Market if the company fails to regain compliance with listing requirements.
The company's product candidates are subject to clinical trial risks and may not receive regulatory approval.
The company is dependent on third-party manufacturers and suppliers, which could lead to supply chain disruptions.
The company may face challenges in commercializing its product candidates and achieving market acceptance.
The company is subject to competition from other biotechnology companies.
The company may need to raise additional capital, which could result in dilution to existing stockholders.
The company is subject to risks associated with the development of new biopharmaceutical products, and may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors, which may adversely affect its business.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development efforts and seeks regulatory approvals for its product candidates. The company is exploring various financing strategies to address its liquidity concerns and continue operations.

Management Comments

Management is currently evaluating different strategies to obtain the required funding of future operations.
Management believes the financial risk associated with cash balances is minimal and has not experienced any losses to date.
Management believes that it has meritorious defenses with respect to the warrant cancellation matter, and intends to vigorously defend its position.
Management believes that results of the SIGNAL-AD study demonstrate that pepinemab has a similar effect in Alzheimers to those previously described for a key outcome in Huntingtons disease.
Management believes that pepinemab may be most effective in patients with early stage symptoms, e.g., Mild Cognitive Impairment (MCI) or Mild Dementia due to AD.

Industry Context

The company's focus on SEMA4D biology and its lead product candidate, pepinemab, positions it in the competitive landscape of neurodegenerative disease and cancer therapeutics. The positive clinical data from the SIGNAL-AD trial is significant in the context of the ongoing search for effective treatments for Alzheimer's disease. The company's approach of combining pepinemab with checkpoint inhibitors in cancer treatment aligns with current trends in immuno-oncology.

Comparison to Industry Standards

The reported net loss of $5.7 million for Q3 2024 is typical for a clinical-stage biotechnology company that is still in the research and development phase and has not yet commercialized any products.
The company's cash position of $2.9 million is relatively low compared to other publicly traded biotech companies, which typically maintain a larger cash runway to fund ongoing clinical trials and operations.
The positive results from the SIGNAL-AD trial, showing a statistically significant increase in brain metabolic activity, are encouraging and could differentiate pepinemab from other Alzheimer's treatments that primarily target amyloid plaques.
The company's approach of combining pepinemab with checkpoint inhibitors in cancer treatment is consistent with the industry trend of exploring combination therapies to enhance efficacy.
The company's ongoing collaboration with Merck and Merck KGaA is similar to other biotech companies that partner with larger pharmaceutical companies to advance their drug development programs.
The company's reliance on private placements and public offerings to raise capital is a common practice for early-stage biotech companies, but it also carries the risk of dilution for existing shareholders.
The company's risk of delisting from Nasdaq is a significant concern, as it could negatively impact investor confidence and the company's ability to raise capital.

Legal Proceedings

A holder of certain warrants that were called for cancellation has notified the company that it believes that the warrants it held are still outstanding, which could lead to adverse impacts for the company.

Related Party Transactions

The company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the company's chairman and major stockholder.
FCMI Parent Co. and Vaccinex (Rochester) L.L.C., which are controlled by the company's chairman and CEO respectively, participated in various private placements and the inducement letter agreement.

Stakeholder Impact

Shareholders face the risk of dilution from future capital raises and potential losses due to the company's financial difficulties.
Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
Creditors may face increased risk of non-payment if the company's financial situation deteriorates further.

Next Steps

The company will continue to analyze data from the SIGNAL-AD trial and plan for future clinical trials.
The company will continue to pursue financing strategies to address its liquidity concerns.
The company will appeal the Nasdaq delisting notice and seek to regain compliance with listing requirements.
The company will continue to advance its cancer programs, including the head and neck and pancreatic cancer trials.
The company will continue to evaluate its development strategy for Huntington's disease.

Key Dates

Date	Description
2020-05-08	The company received a loan under the Small Business Administration's Paycheck Protection Program.
2021-11-08	The company was awarded loan forgiveness of $876,171 and the remaining balance of the loan was refinanced.
2023-03-30	The company entered into a Stock Purchase Agreement, pursuant to which the Company issued and sold 23,693 shares of its common stock at a purchase price of $86.10 per share for aggregate gross proceeds of $2.04 million.
2023-09-25	The company effected a 1-for-15 reverse stock split of its issued shares of common stock.
2023-10-03	The company sold shares of common stock and warrants in a public offering.
2024-02-06	The company entered into a securities purchase agreement pursuant to which it issued and sold shares of common stock and warrants.
2024-02-19	The company effected a second reverse split of shares of the Company's common stock on a 1-for-14 basis.
2024-03-27	The company entered into a securities purchase agreement pursuant to which the Company issued and sold 193,000 shares of the Company's common stock in a public offering together with private placement warrants.
2024-03-28	The company entered into a securities purchase agreement with the Alzheimers Drug Discovery Foundation.
2024-04-11	The company received a letter from Nasdaq notifying the company that it no longer complies with the minimum stockholders equity requirement.
2024-06-05	Nasdaq notified the company that it has been provided an extension to regain and evidence compliance with the Equity Standard on or before September 30, 2024.
2024-07-18	The 142,857 pre-funded warrants were exercised and converted to common shares.
2024-07-31	SIGNAL-AD topline data was reported at the Alzheimer's Association International Conference.
2024-09-17	The company entered into inducement letter agreements with holders of existing warrants.
2024-10-07	The company received a letter from the Nasdaq Listing Staff stating that the Company had not regained compliance with the Equity Standard or the Alternatives Standards.
2024-10-31	Additional efficacy data for SIGNAL-AD was reported at the Clinical Trials on Alzheimers Disease Conference.
2024-11-13	The company entered into a securities purchase agreement pursuant to which the Company issued and sold to the purchasers named therein an aggregate of 76,909 shares of the Companys common stock and pre-funded warrants to purchase up to 584,646 shares of Common Stock.
2024-11-14	The Private Placement closed for aggregate gross proceeds to the Company of approximately $2.15 million.

Keywords

Vaccinex, pepinemab, Alzheimer's disease, Huntington's disease, cancer, clinical trial, biotechnology, SEMA4D, Nasdaq, warrants, financial results, drug development, immunotherapy

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.